The Bioadaptor coronary implant maintains safe long-term outcomes, compared with contemporary drug-eluting stents (DES), for the treatment of clinically complex, high-risk patients with acute coronary syndrome (ACS), an analysis of the INFINITY-SWEDEHEART trial shows.